[go: up one dir, main page]

FI933909A0 - Anvaendning av molekyler riktade mot receptorer pao cellytan foer behandling av virussjukdomar - Google Patents

Anvaendning av molekyler riktade mot receptorer pao cellytan foer behandling av virussjukdomar

Info

Publication number
FI933909A0
FI933909A0 FI933909A FI933909A FI933909A0 FI 933909 A0 FI933909 A0 FI 933909A0 FI 933909 A FI933909 A FI 933909A FI 933909 A FI933909 A FI 933909A FI 933909 A0 FI933909 A0 FI 933909A0
Authority
FI
Finland
Prior art keywords
virussjukdomar
riktade
receptorer
molekyler
cellytan
Prior art date
Application number
FI933909A
Other languages
English (en)
Finnish (fi)
Inventor
Jean C Nichols
Original Assignee
Seragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seragen Inc filed Critical Seragen Inc
Publication of FI933909A0 publication Critical patent/FI933909A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI933909A 1991-03-07 1993-09-07 Anvaendning av molekyler riktade mot receptorer pao cellytan foer behandling av virussjukdomar FI933909A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66576291A 1991-03-07 1991-03-07
PCT/US1992/001705 WO1992015318A1 (fr) 1991-03-07 1992-03-05 Utilisation de molecules ciblees sur des recepteurs de surface de cellules pour le traitement des maladies virales

Publications (1)

Publication Number Publication Date
FI933909A0 true FI933909A0 (fi) 1993-09-07

Family

ID=24671481

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933909A FI933909A0 (fi) 1991-03-07 1993-09-07 Anvaendning av molekyler riktade mot receptorer pao cellytan foer behandling av virussjukdomar

Country Status (8)

Country Link
US (1) US6074636A (fr)
EP (1) EP0721340A1 (fr)
JP (1) JPH06508821A (fr)
AU (1) AU1643692A (fr)
CA (1) CA2104958A1 (fr)
FI (1) FI933909A0 (fr)
NO (1) NO933171L (fr)
WO (1) WO1992015318A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2596600A (en) 1998-12-31 2000-07-31 Chiron Corporation Modified hiv env polypeptides
US6602705B1 (en) * 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2369762A1 (fr) * 1999-04-16 2000-10-26 Peter P. Lee Procede destine a ameliorer la demi-vie de ligands solubles specifiquement viraux sur des membranes de muqueuses
EP1418936A2 (fr) * 2001-05-09 2004-05-19 Alk-Abell A/S Compositions pharmaceutiques destines a prevenir ou traiter les maladies associees aux cellules th1 et th2 par modulation du rapport th1/th2
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
WO2003004657A1 (fr) * 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2003020876A2 (fr) * 2001-08-31 2003-03-13 Chiron Corporation Polynucleotides codant des polypeptides de type b du vih antigeniques, polypeptides et leurs utilisations
AU2003219730A1 (en) * 2002-02-07 2003-09-02 Massachusetts Institute Of Technology Anti-pathogen treatements
ES2401136T3 (es) 2002-11-15 2013-04-17 Genmab A/S Anticuerpos monoclonales humanos contra CD25
AU2008254578B2 (en) * 2007-05-21 2013-06-06 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
SG183742A1 (en) 2007-05-21 2012-09-27 Alderbio Holdings Llc Antibodies to il-6 and use thereof
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066369A2 (fr) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonistes de l'il-6 destinés à faire augmenter l'albumine et/ou à faire baisser la crp
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
US20160108122A1 (en) * 2013-05-23 2016-04-21 Idac Theranostics, Inc. Therapeutic or prophylactic agent for immunodeficiency virus infection
US20220062390A1 (en) 2020-08-26 2022-03-03 Dr. Reddy's Laboratories Sa Methods of treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340494C (fr) * 1988-05-19 1999-04-13 The Beth Israel Hospital Association And Brigham And Women's Hospital Induction de tolerance a un antigene etranger
ZA902949B (en) * 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
WO1991001004A1 (fr) * 1989-07-06 1991-01-24 Seragen, Inc. Molecules hybrides
CA2086679A1 (fr) * 1990-07-05 1992-01-06 Hermanus A. M. Verheul Conjugues contenant une toxine dirigee contre un recepteur

Also Published As

Publication number Publication date
AU1643692A (en) 1992-10-06
US6074636A (en) 2000-06-13
CA2104958A1 (fr) 1992-09-08
EP0721340A4 (fr) 1995-08-11
NO933171L (no) 1993-11-11
EP0721340A1 (fr) 1996-07-17
WO1992015318A1 (fr) 1992-09-17
JPH06508821A (ja) 1994-10-06
NO933171D0 (no) 1993-09-06

Similar Documents

Publication Publication Date Title
FI933909A0 (fi) Anvaendning av molekyler riktade mot receptorer pao cellytan foer behandling av virussjukdomar
FI931627L (fi) Foerfarande foer producering av tecken pao diamanter
FI924781A0 (fi) Foerfarande foer matning av kvaeve fraon en anlaeggning pao platsen
FI920617L (fi) Konversion av kolmonoxid med katalysatorer baserade pao blandade oxiderav oevergaongsmetaller
FI924079L (fi) Mot frysning skyddande transportenheter
FI915314L (fi) Anordning foer avlagring av en metaloxidbelaeggning pao glasartiklar
PT100087A (pt) Novos esteres de esteroides
FI933510A0 (fi) Graensytaktiva foereningar baserade pao modifierade risinoljefettderivat
FI931773A0 (fi) Pao en masspektrometer baserat kontinuerligt utslaeppsoevervakningssystemfoer maetning av roekgaser fraon farligt avfall
FI930681L (fi) Saerskilt foer granskning av registerplaotarna pao fordon avsedd oevervakningsanordning
FI922878L (fi) Foerfarande foer ympning av vinylmonomerer pao partikelformiga olefinpolymerer
DE69209219D1 (de) Photovervielfacher
FI922339L (fi) Anvisningsskylt pao landnings- eller stratbanor pao flygfaelt
FI934235L (fi) Kommunikations- och styrsystem pao en fast mobilradiostation
FI934716A (fi) Separationsanordning foer luft/aonga
FI933395A0 (fi) Pao undecylensyraester baserat desodoriseringsmedel foer papperindustrins avlopp
FI915113L (fi) Foerfarande foer att inspela en flerkanalsaudiosignal pao en CD-skiva
FI932055L (fi) Foerfarande foer betahaerdning av skyddshoeljet pao kaernbraensle
FI933763L (fi) Graensytaktiva foereningar baserade pao alkoxylerade fettaminer
FI933183L (fi) Kopplingsnaet av pao ingaongssidan parallellt kopplade kopplingsenheter foer digitala foermedlingssystem
FI931756A0 (fi) Anordning foer oevervakning av nivaon pao en vaetskeyta
FI935011A0 (fi) Mellanvaeggsystem i synnerhet foer hyttdaeck pao fartyg
FI922418L (fi) Anordning foer laosning av en lastbaerare pao en jaernvaegsvagns svaengram
FI922417L (fi) Anordning foer laosning av en svaengram pao en jaernvaegsvagn
FI930488L (fi) Anordning foer att ordna en arkbunt pao nytt cykliskt

Legal Events

Date Code Title Description
FA Application withdrawn